Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

NCT02961218 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Anemia

Interventions

DRUG: ACZ885
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals